Ionized hypocalcemia prior to continuous veno-venous hemodialysis initiation: prevalence and consequences Authors: Baptiste Thibault, Thomas Rimmelé, Matthieu Petit, Robert Pohlmeier, Marion Calmettes, Nicolas Chardon, Jean-François Carabalona, Florent Wallet, Frank Bidar Published: 2026 ABSTRACT AbstractRegional citrate anticoagulation (RCA) is currently the first-line strategy during continuous renal replacement therapy (CRRT). No international recommendation exists concerning the assessment of ionized calcium (iCa) prior to RCA-CRRT initiation and data on the consequences of pre-existing ionized hypocalcemia are lacking. This study aimed to investigate the frequency of iCa measurements prior to RCA-CRRT and assess the consequences of ionized hypocalcemia in patients undergoing RCA-CRRT. This retrospective, single-center study included all patients treated with RCA-CRRT between June 2021 and April 2023. Calcium target range was considered achieved during RCA-CRRT when the iCa levels were stable within the protocol range (1.12—1.20 mmol/L) over two consecutive measurements performed in a 6-h timeframe. RCA-CRRT related adverse events were screened during the first 72 h of RCA-CRRT. Among the 200 patients screened, 117 (59%) had an iCa measurement prior to RCA-CRRT initiation. Among them, 70 (60%) had normal iCa concentration, 22 (19%) had hypocalcemia which was corrected by calcium chloride, and 25 (21%) had ionized hypocalcemia without any correction prior to CRRT initiation. In all patients presenting hypocalcemia, mean iCa reached normal values 12 h after RCA-CRRT initiation. Calcium target range was achieved in 59 (50%) patients within the first 72 h, whereas only 5 (4.3%) of subjects that remained on CRRT at 72 h failed to achieve homeostasis. Patients who presented with severe hypocalcemia (< 1 mmol/L) during the first 12 h of RCA-CRRT had more frequently pre-existing severe hypocalcemia. Ionized calcium blood measurement is not systematically performed prior to RCA-CRRT initiation. However, within the 12 h following RCA-CRRT initiation, most patients achieved normal calcium concentrations including those with pre-existing hypocalcemia.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12871-026-03894-w.Keywords: Continuous renal replacement therapy, Hemodialysis, Hypocalcemia, Regional citrate anticoagulation Background Acute kidney injury (AKI) in intensive care remains a significant clinical challenge associated with poor prognosis. Approximately 10% of critically ill patients require renal replacement therapy (RRT) during their intensive care unit (ICU) stay, with reported mortality rates of 50% [1]. Continuous renal replacement therapy (CRRT) is commonly used in ICU patients especially when they are hemodynamically unstable. Current guidelines recommend regional citrate anticoagulation (RCA) as first-line strategy for anticoagulation during CRRT in patients without contraindications to citrate administration [2]. The advantages of RCA include a reduced bleeding risk and an increase of CRRT hemofilter lifespan compared to anticoagulation with systemic heparin [3]. RCA involves pre-filter administration of citrate to chelate ionized calcium (iCa), thereby inhibiting the clotting cascade within the filter. Replacement of calcium is performed via the post-filter circuit or a separate line. Precise calcium supplementation is crucial for safety and effectiveness of RCA. Inadequate calcium supplementation, however, can lead to serious complications such as hypocalcemia, or filter clotting [2, 4, 5]. However, although major guidelines recommend RCA as the first-line anticoagulation strategy for CRRT and emphasize calcium monitoring during treatment, they do not always explicitly require a pre-treatment ionized calcium measurement before RCA-CRRT initiation [2, 6, 7]. Standard citrate-based CRRT protocols include an assessment of postfilter iCa concentration shortly after initiating RCA-CRRT [8]. This pre-treatment evaluation may be essential to assess if an abnormality in calcium concentration already exists related to the patients’ underlying condition. It could also help prevent metabolic complications associated with RCA or avoid the risks of hypocalcemia that can impair cardiac contractility or induce arrhythmias [9, 10]. However, no study has explored the incidence and consequences of hypocalcemia prior to RCA-CRRT initiation. A decade after the implementation of RCA-CRRT as first-line treatment in our institution, we aimed to investigate the frequency and consequences of iCa concentration measurements prior to RCA-CRRT in a cohort of critically ill patients undergoing RCA-CRRT. The primary objective was to describe the change in iCa over the time course of RCA-CRRT according to the iCa status prior to RCA-CRRT initiation (normocalcemia or hypocalcemia). The secondary objective was to assess RCA-CRRT related adverse events and outcomes according to iCa status prior to treatment initiation. Methods Study design and recruitment A retrospective study was conducted in two medico-surgical and surgical ICUs at the Edouard Herriot hospital Lyon, France) and included all consecutive patients with AKI treated by RCA-CRRT between June 2021 and April 2023. These ICUs have a combined capacity of 35 beds. The IRB (Comité Scientifique et Ethique des HCL, CSE-HCL – IRB 00013204) approved the study (ref. 24—5018). In accordance with French legislation for retrospective studies based on routine care data, patients and/or their families received an information letter informing them of the use of their data for research purposes and providing the opportunity to object, none were opposed to the use of their data for research purposes. RCA-CRRT protocol A weight-adapted protocol for CVVHD with RCA, based on the protocol by Morgera et al. [6], was employed for all patients requiring RCA-CRRT. CVVHD was conducted using the multiFiltratePRO® RRT machine (Fresenius Medical Care AG, Bad Homburg, Germany), with blood flow rates set to maintain a 3:1 blood flow to dialysate flow ratio. For patients at high risk of citrate accumulation, a 2:1 ratio could be set. RCA was achieved by infusing a 4% trisodium citrate solution into the access line of the extracorporeal circuit, starting at a dose of 4 mmol/L of blood. Calcium target range was considered achieved when the iCa levels were stable, within the protocol range (1.12—1.20 mmol/L), over two consecutive measurements performed in a 6-h timeframe. Citrate infusion rate was adjusted to maintain post-filter iCa levels between 0.25 and 0.35 mmol/L [11]. Calcium substitution was initiated at 1.7 mmol of calcium per liter of total effluent flow and was adjusted to maintain patients' iCa within the physiological range of 1.12 to 1.20 mmol/L (Supplementary Tables A and B). The dialysate flow was set to target a delivered dose of 20—25 mL/Kg/h except for patients at risk of citrate accumulation for whom the dialysate flow could be increased to facilitate calcium-citrate complexes elimination. Citrate and calcium solutions were infused via the integrated pumps of the RCA-CRRT machine. Filters were routinely changed every 72 h, as per the manufacturer's instructions. According to the local protocol, iCa had to be measured prior to initiating RCA-CRRT. In case of iCa below 1.1 mmol/L, the protocol consists in the intravenous administration of 2 g of calcium chloride. Metabolic disorders and RCA-CRRT related adverse events The diagnosis of citrate accumulation was based on the following established biological criteria: (1) iCa < 1.10 mmol/L; (2) an increased total to ionized calcium ratio (≥ 2.25); (3) significant metabolic acidosis (pH < 7.2); and (4) an elevated anion gap (> 16 mmol/L). Citrate accumulation was suspected when three of these criteria were present [12, 13]. Accumulation criteria were assessed irrespective of subsequent protocol modifications, as the objective was to capture the occurrence of citrate accumulation during treatment rather than only under unchanged protocol conditions. Net citrate overload is a different phenomenon that occurs in case of excessive citrate administration or inadequate clearance of calcium-citrate complexes by the hemofilter. The concomitant net load of sodium ions leads to plasma alkalinization inducing an increase of the strong ion difference. It was diagnosed in case of metabolic alkalosis (defined as pH > 7.42 and pCO2 between 35 and 45 mmHg, HCO3- > 26 mEq/L with a normal total to ionized calcium ratio, i.e. < 2.25) [13]. Excess of dialysate delivery results in insufficient trisodium citrate delivery, leading to residual metabolic acidosis due to inadequate buffering of AKI-associated acidosis. This situation arises when blood flow is set too low relative to dialysate flow, as a bicarbonate-reduced dialysate is employed. Excess of dialysate delivery was defined as follows: metabolic acidosis (pH < 7.34 with a normal pCO2) unexplained by an increase in lactate concentration, a blood-to-dialysate flow ratio > 2:1, and a normal total to ionized calcium ratio (< 2.25). Citrate accumulation must be excluded before considering an excess of dialysate delivery. Data collection Patients’ demographics collected included age, sex, body mass index, reason for admission, reason for initiating RCA-CRRT, presence of chronic kidney disease, and Sequential Organ Failure Assessment (SOFA) score. We also recorded the use of norepinephrine before and 24 h after RCA-CRRT initiation, as well as red blood cell administration during the first 24 h of RCA-CRRT. Biochemical data included sodium, potassium, chloride, creatinine, protein, total calcium, activated partial thromboplastin time. Blood gas analyses (pH, pCO2, standard bicarbonate, and lactate) were performed on ABL800 Flex (Radiometer Medical ApS, Brønshøj, Denmark) every 6 h during RCA-CRRT. Ionized calcium was considered as measured prior to RCA-CRRT initiation only if it had been performed within a 12-h window before RCA-CRRT initiation. This 12-h threshold reflected our local protocol, under which a new iCa measurement was usually not required before RCA-CRRT initiation when a value was already available from the previous 12 h and no major change in metabolic status had occurred. If no iCa measurement was available during this timeframe, patients were classified as having no measurement of iCa. Patients with an iCa measurement were then divided into three groups. If iCa was 1.1 mmol/L or higher, patients were considered to start RCA-CRRT in normocalcemia. If iCa was lower than 1.1 mmol/L, patients were considered to start RCA-CRRT in hypocalcemia. In case of hypocalcemia corrected with 2 g of calcium chloride administration, patients were considered as “hypocalcemia + IV correction” (Fig. 1). This intravenous supplementation corresponded to a fixed correction step of our local protocol rather than an individualized dose adjustment. In routine practice, calcium chloride was administered after the decision to start CRRT and before actual connection to the circuit. A systematic re-check of iCa before RCA-CRRT initiation was not required, to avoid delaying treatment initiation in critically ill patients. Severe ionized hypocalcemia was defined as iCa < 1 mmol/L [14]. Preexisting hypocalcemia was defined using the closest ionized calcium measurement available within the 12 h preceding RCA initiation. Flow chart. iCa: ionized calcium. RCA-CRRT: regional citrate anticoagulation continuous renal replacement therapy RCA-CRRT parameters, including the duration of RCA-CRRT, post-filter iCa levels, and the flow rates of blood, citrate, dialysate, and calcium, were systematically recorded. These parameters were measured at 6-h intervals to ensure precise monitoring and adjustment. In the present study, biological parameters were monitored at 6-h intervals for 24 h and at 24-h intervals between 24 and 72 h following RCA-CRRT initiation. Statistical analysis Qualitative variables are presented as numbers and percentages and quantitative variables as medians and 25th/75th percentiles. Chi square or Fisher’s exact tests were used for qualitative variable assessment. Quantitative variables were compared with Mann–Whitney U test or Kruskal–Wallis test, as appropriate. When variables were compared over time, and to account for multiple testing, p-values were then adjusted using the Bonferroni method. Multivariable logistic regression was performed to assess the association between variables of interest and mortality. The multivariable model was exploratory and included clinically relevant variables selected a priori to reflect baseline severity, metabolic status, and clinical context at RCA-CRRT initiation, namely age, SOFA score, pH, septic shock, and hypocalcemia status with or without intravenous calcium correction. Results are reported as odds ratios with 95% confidence intervals and p-values. All analyses were conducted on a complete-case basis. All reported p-values are two-sided. The level of significance was set at 5%. All statistical analyses were performed with R software v4.3.1. Results Patients’ characteristics From June 2021 to April 2023, a total of 200 patients with AKI received RCA-CRRT; among them, 117 (59%) had an iCa measurement prior to RCA-CRRT (Fig. 1, Supplementary Table C). Compared with patients with a pre-treatment iCa measurement, those without such a measurement had a similar SOFA score at RCA initiatiotan, but were more often admitted for septic shock. Among the 117 patients with an iCa measurement, the median SOFA score was 14 [12–15] and 79 (68%) were admitted to the ICU for surgical purposes. Septic shock was present in 92 (79%) patients at RCA-CRRT initiation, while 41 (35%) patients presented with hemorrhagic shock. The primary indications for RCA-CRRT were anuria in 87 (74%) patients and metabolic acidosis in 77 (66%) patients. Among the patients with an iCa measurement, 70 (60%) had normal iCa concentration (normocalcemia group), 22 (19%) had hypocalcemia with calcium chloride administration prior to RCA-CRRT initiation (hypocalcemia + IV correction group), and 25 (21%) had ionized hypocalcemia without any correction before RCA-CRRT (hypocalcemia group). Baseline characteristics did not differ significantly between the different groups (Table 1). Table 1Baseline characteristics in patients with normal calcium concentration levels and hypocalcemia prior to RCA-CRRTPopulation (n = 117)Normal Ionized Calcium (n = 70)Hypocalcemia and IV correction (n = 22)Hypocalcemia (n = 25)p-valueDemographics Age, years66 [56—72]65 [56—70]66 [54—75]66 [61—73]0.3 BMI, kg/m227 [23—31]27 [23—31]28 [24—31]27 [24—33]0.8 Chronic Kidney Disease, n (%)19 (16%)11 (16%)3 (14%)5 (20%)0.9 SOFA score14 [12 - 15]13 [12 - 15]14 [11 - 16]15 [13 - 16]0.4Context of ICU admission Surgical, n (%)79 (68%)47 (67%)13 (59%)19 (76%) Medical, n (%)38 (33%)23 (33%)9 (40%)6 (24%) Septic shock, n (%)92 (79%)52 (74%)17 (7%)23 (92%)0.2 Hemorrhagic shock, n (%)41 (35%)29 (41%)8 (36%)4 (16%)0.07 Cardiogenic shock, n (%)22 (19%)10 (14%)5 (23%)7 (28%)0.3CRRT indication Hyperkaliemia, n (%)46 (39%)30 (43%)8 (36%)8 (32%)0.6 Metabolic acidosis, n (%)77 (66%)47 (67%)12 (55%)18 (72%)0.4 Uremic syndrome, n (%)15 (13%)6 (8.6%)5 (23%)4 (16%)0.2 Anuria, n (%)87 (74%)46 (66%)19 (86%)22 (88%)0.03CRRT parameters Blood flow (mL/min)100 [100—120]100 [100—120]100 [100—120]100 [100—120]0.02 Dialysate flow (mL/h)2400 [2000—3000]2400 [2000—3000]2500 [4000—3000]2400 [2000—3000]0.1Biological at CRRT initiation pH7.2 [7.1—7.3]7.2 [7.1—7.3]7.3 [7.2—7.3]7.2 [7.1—7.3]0.2 Lactate, mmol/L5.7 [2.5—9.7]5.6 [2.3—9.7]5.3 [2.4—8.6]8 [3.2—11]0.4 Sodium, mmol/L137 [134—142]138 [134—141]137 [132—144]136 [134—142]0.9 Potassium, mmol/L5 [4.5—5.6]5. [4.7—5.6]4.9 [4.5—6.2]4.9 [4.3—5.7]0.9 Chloride, mmol/L107 [102—110]107 [103—112]108 [102—110]106 [100—108]0.08 Bicarbonate, mmol/L16 [13 - 19]16 [12 - 19]18 [14 - 19]17 [14 - 18]0.5 Creatinine, µmol/L220 [128—329]197 [115—297]262 [151—360]230 [150—310]0.4 Serum proteins, g/L47 [40—57]47 [41—57]48 [40—59]46 [37—56]0.8 Bilirubin, µmol/L16 [15 −32]16 [8—33]21 [12—27]19 [13—32]0.5 Prothrombin time activity, %56 [44—73]53 [42–75]63 [57—66]53 [46–66]0.4 Ionized calcium concentration before CRRT initiation, mmol/L1.1 [1.1—1.2]1.2 [1.1—1.3]1.0 [1.0—1.1]1.0 [1.0—1.1] < 0.001 Norepinephrine at CRRT initiation, n (%)114 (97%)67 (96%)22 (100%)25 (100%)0.4 RBC administration during the first 24 h63 (55%)39 (57%)12 (55%)12 (48%)0.3Data are presented as median [IQR] unless otherwise specifiedBMI body mass index, CRRT continuous renal replacement therapy, RBC red blood cell, RCA regional citrate anticoagulation, SOFA sequential organ failure assessment Baseline characteristics in patients with normal calcium concentration levels and hypocalcemia prior to RCA-CRRT Data are presented as median [IQR] unless otherwise specified BMI body mass index, CRRT continuous renal replacement therapy, RBC red blood cell, RCA regional citrate anticoagulation, SOFA sequential organ failure assessment Calcium and citrate target range during RCA-CRRT In the normocalcemia group, iCa concentration tended to decrease at 6 h after RCA-CRRT initiation and remained stable within the protocol range values during the therapy. Despite calcium chloride administration before RCA-CRRT initiation, patients in the hypocalcemia + IV correction group presented persistently decreased iCa concentration at 6 h after CRRT initiation. In both groups of patients presenting hypocalcemia prior to RCA-CRRT initiation, iCa concentration was significantly lower at 6 h compared to patients with normocalcemia but reached higher values at 12 h after RCA-CRRT initiation. After 12 h, iCa concentration remained stable and above the lowest range during the first 72 h of RCA-CRRT (Fig. 2A). Time course of ionized calcium concentration, citrate flow rate, and calcium substitution during RCA-CRRT. A time course of systemic ionized calcium concentration. B time course of citrate dose, expressed in mmol of citrate infused per liter of treated blood. C time course of calcium substitution rate, expressed in mmol of Ca infused per liter of effluent. D time course of total-to-ionized calcium ratio. Red line: patients with normal ionized calcium concentration before RCA-CRRT initiation. Blue line: patients with hypocalcemia and intravenous correction (2 g of calcium chloride) before RCA-CRRT initiation. Green line: patients with hypocalcemia prior to RCA-CRRT initiation. Data are presented as mean value with 95% confidence intervals. Variables were compared between groups at each time point (at CRRT initiation and 6 h, 12 h, 24 h, 48 h or 72 h after CRRT initiation) using the Kruskal–Wallis test. To account for multiple comparisons, p-values were adjusted using the Bonferroni method. Only statistically significant comparisons are reported in the figure, with * indicating p < 0.05. The number of available observations at each time point is displayed below each panel Citrate flow remained constant in the normocalcemia group and was significantly higher at 6 h than in the groups of patients with hypocalcemia prior to RCA-CRRT initiation (Fig. 2B). Similarly, the calcium substitution rate initially increased during the first 12 h of RCA-CRRT in both groups of patients presenting with hypocalcemia prior to RCA-CRRT compared to the normocalcemia group (Fig. 2C). Concerning calcium target range, 59 (50%) patients achieved calcium concentration homeostasis within the first 72 h. The proportion of patients who failed to reach calcium target range did not differ significantly between groups. Only 5 (4.3%) patients failed to achieve calcium target range within 72 h, and 38 (33%) patients died before reaching calcium concentration homeostasis (Supplementary Table D). RCA-CRRT-related adverse events and outcomes Among the 117 patients, common adverse events associated with RCA-CRRT occurred in 15 (13%) patients. Citrate accumulation was observed in 6 (5%) patients and did not differ significantly between groups. Citrate accumulation occurred in all affected patients between 6 and 24 h after CRRT initiation. No significant difference in the incidence of net citrate overload or excess of dialysate delivery was reported. Mortality was higher in the hypocalcemia group who did not receive IV calcium replacement prior to CRRT initiation (Table 2). However, this association was no longer observed after adjustment for age, SOFA score, pH, septic shock, and hypocalcemia status with or without IV calcium correction. In the multivariable model, hypocalcemia without IV correction was not independently associated with mortality (OR 1.2, 95% CI 0.39–3.91; p = 0.74), nor was hypocalcemia with IV correction (OR 0.39, 95% CI 0.10–1.24; p = 0.13), whereas lower pH remained independently associated with mortality (OR 0.49 per 0.1 increase, 95% CI 0.31–0.71; p < 0.001) (Supplementary Table F). Table 2RCA-CRRT related adverse events and mortalityPopulation (n = 117)Normal Ionized Calcium (n = 70)Hypocalcemia and IV correction (n = 22)Hypocalcemia (n = 25)p-valueCitrate Accumulation6 (5.2%)3 (4.4%)1 (4.6%)2 (8.3%)0.8Net citrate overload2 (1.7%)0 (0.0%)1 (4.6%)1 (4.2%)0.1Excess of dialysate delivery7 (6.0%)5 (7.1%)1 (4.6%)1 (4.2%)0.9Death52 (44.4%)32 (45.7%)5 (22.7%)15 (60.0%)0.04Data are presented as n (%)CRRT continuous renal replacement therapy, RCA regional citrate anticoagulation RCA-CRRT related adverse events and mortality Data are presented as n (%) CRRT continuous renal replacement therapy, RCA regional citrate anticoagulation We also analyzed the occurrence of severe ionized hypocalcemia (iCa < 1 mmol/L) during the first 12 h of treatment as the lowest iCa values were observed within this timeframe. Among the 95 patients alive at 12 h of RCA-CRRT, 30 (32%) developed severe ionized hypocalcemia: these patients more frequently presented with severe hypocalcemia prior to RCA-CRRT and citrate accumulation (Table 3). Table 3Patients’ characteristics depending on the occurrence of severe hypocalcemia within the first 12 h of RCA-CRRTAlive at 12 h of RCA-CRRT (n = 95)Absence of severe ionized hypocalcemia (n = 65)Severe Ionized hypocalcemia (n = 30)p-valueSOFA at RCA-CRRT initiation13 [11- 15]13 [12 - 15]14 [11 - 16]0.9Severe hypocalcemia prior to CRRT initiation, n (%)12 (13%)2 (3.2%)10 (33%)0.001Citrate Accumulation, n (%)6 (6.4%)0 (0%)6 (20%)0.001Excess of dialysate flow rate, n (%)7 (7.4%)6 (9.2%)1 (3.3%)0.4Death, n (%)33 (35%)22 (34%)11 (37%)0.9Data are presented as median [IQR] unless otherwise specifiedCRRT continuous renal replacement therapy, RCA regional citrate anticoagulation, SOFA sequential organ failure assessment Patients’ characteristics depending on the occurrence of severe hypocalcemia within the first 12 h of RCA-CRRT Data are presented as median [IQR] unless otherwise specified CRRT continuous renal replacement therapy, RCA regional citrate anticoagulation, SOFA sequential organ failure assessment Discussion Despite the existence of a local protocol stating that iCa must be measured and hypocalcemia corrected prior to RCA-CRRT initiation, the present study shows that this measurement was lacking in nearly 40% of patients and that RCA-CRRT was initiated in some patients with pre-existing hypocalcemia. Although iCa concentrations tended to normal values within 12 h after RCA-CRRT initiation in both patients with normocalcemia and hypocalcemia, the risk of severe hypocalcemia was higher in patients with pre-existing hypocalcemia. The present study was performed in a representative group of critically ill patients treated with standardized RCA-CRRT. Hypocalcemia is a common electrolyte disturbance in both medical and surgical ICU patients, the reported prevalence of which varies widely across studies, reflecting differences in patient populations and the diagnostic thresholds used, with rates ranging from 15 to 88% [15, 16]. In the present cohort, iCa was not measured in approximately 40% of cases, and hypocalcemia was not consistently corrected. This is concerning, as RCA-CRRT can potentially exacerbate ionized hypocalcemia, highlighting the need for more rigorous calcium management before initiating RCA-CRRT. Nevertheless, in patients with pre-existing hypocalcemia, iCa concentrations tended to be corrected by 12 h after CRRT initiation. Moreover, among the patients who underwent RCA-CRRT for at least 72 h, the large majority of them achieved calcium target range within these first 72 h. These findings suggest that the proposed RCA-CVVHD protocol may allow progressive correction of calcium disturbances over time when citrate infusion and calcium substitution rates are applied according to the CRRT protocol [6]. In this respect, the study by Sheng et al. proposed an RCA-CRRT management algorithm incorporating pre-session blood calcium into the initial calcium supplementation strategy, with subsequent adjustment during treatment [17]. In their study, as in ours, patients with lower baseline calcium levels showed an increase in iCa over time linked to an increase calcium imput, whereas those with higher initial levels showed an early decrease, with both groups tending to converge toward a similar target iCa range during treatment. These observations suggests that baseline calcium status could be taken into account when designing initial calcium supplementation protocols [18]. It is worth noting however, that a slight decrease in iCa within 2 to 4 h of treatment has previously been described with RCA-CVVHD [19]. Such an early decrease could not be assessed in the present study because iCa monitoring was performed every 6 h and no repeated measurements were available within the first 4 h after RCA-CRRT initiation. Accordingly, some early declines in iCa may have been missed, particularly in unstable patients, which should be considered when interpreting the early calcium trajectory. This further emphasizes the importance of correcting pre-existing hypocalcemia before RCA-CRRT initiation. Studies from centers with extensive experience with RCA report low rates of RCA-related complications such as citrate accumulation in critically ill patients [12, 19, 20]. Citrate accumulation in the current study was diagnosed based on ionized hypocalcemia in combination with an elevated tCa/iCa ratio and metabolic acidosis with an elevated anion gap. The incidence of citrate accumulation in patients was low herein and was not associated with the existence of hypocalcemia prior to RCA-CRRT initiation. This finding is comparable to previously reported frequencies of citrate accumulation [12, 20]. The incidence of net citrate overload and excess of dialysate delivery were also low, however, given the small size of the hypocalcemia subgroups and the rarity of these events, these estimates should be regarded as descriptive only and interpreted with caution. Regarding the occurrence of severe hypocalcemia, a previous study reported an incidence of ionized hypocalcemia (iCa < 1.05 mmol/L) in 25% of patients undergoing RCA-CRRT, with severe hypocalcemia (defined as iCa < 0.95 mmol/L) occurring in 1.3% of cases [21]. A significant association exists between hypocalcemia and hypotension during RCA-CRRT, which is further linked to an increase in hospital mortality [14, 22]. In the present study, the occurrence of severe hypocalcemia (iCa < 1 mmol/L) during the first 12 h was associated with the existence of pre-existing severe hypocalcemia. This is consistent with the findings of Sheng et al., who reported that a decrease in iCa concentration was more likely to occur in patients with pre-session hypocalcemia using an algorithm based approach [17]. In line with this concept, our findings suggest that patients with pre-existing hypocalcemia may be more exposed to early hypocalcemia during RCA-CRRT. This raises the hypothesis that a calcium supplementation protocol in which the initial calcium infusion rate is adapted to pre-treatment calcium level might reduce this risk. However, our data do not allow us to determine whether such an approach would be preferable to immediate intravenous calcium correction before CRRT initiation, or whether a combined strategy—intravenous correction before initiation together with a calcium supplementation protocol in which the initial calcium infusion rate is adjusted to baseline calcium status—might allow more rapid normalization of iCa. In addition, because no standardized interval was defined between intravenous calcium administration and RCA-CRRT initiation, and because iCa was not systematically rechecked before connection to the circuit, early iCa values after treatment initiation may have reflected both the effect of the RCA-CRRT protocol itself and the transient effect of the initial intravenous calcium correction. These different approaches should therefore be regarded as hypotheses requiring prospective comparison. Nevertheless, as previously discussed, iCa tended to raise up to normal values within the first 12 h in the groups of patients with hypocalcemia, suggesting that the occurrence of severe hypocalcemia may be attributable to previous underlying conditions rather than RCA-CRRT itself in most patients. More broadly, hypocalcemia may be associated with other disturbances, including altered parathyroid hormone regulation in critical illness [23]. In contrast, clinically relevant effects on coagulation are usually observed only at lower ionized calcium levels [24]. Overall, although the risk of RCA-related adverse events may be low, measuring iCa prior to RCA-CRRT initiation may be useful to document patients’ baseline condition and to determine whether hypocalcemia is associated with other risk factors not related to RCA-CRRT. Furthermore, severe hypocalcemia is common during the first hours of RCA-CRRT and could be associated with increased mortality [22]. Finally, given that citrate accumulation is defined by the existence of severe hypocalcemia during RCA-CRRT, any uncorrected pre-existing hypocalcemia could worsen the magnitude of hypocalcemia observed in this situation. Pre-existing hypocalcemia may also complicate the early recognition of citrate accumulation, by making the interpretation of calcium changes more difficult. All these considerations support careful monitoring of iCa and subsequent correction, if necessary, in patients receiving RCA-CRRT. There are several limitations to the present study, including its single-center design. However, patients were admitted to two ICUs with different areas of expertise and presented a comprehensive range of conditions. In addition, the number of patients with hypocalcemia prior to RCA-CRRT was low, possibly impacting statistical power and limiting group comparisons. Missing data at later time points, mainly related to treatment discontinuation, death, or ICU discharge, may also have further reduced the precision of longitudinal comparisons. Accordingly, estimates for uncommon complications, such as citrate accumulation, net citrate overload, and excess of dialysate delivery, should be interpreted cautiously, particularly in subgroup analyses. Although the observed frequencies were in the range of those reported in other large studies [12, 25], our study was not powered to draw firm conclusions regarding these rare events. Moreover, we employed surrogate criteria to evaluate citrate accumulation rather than directly measuring citrate levels; this is because measurement of blood citrate concentration is not feasible in routine laboratory practice and the parameters we used are widely accepted. Another limitation relates to the definition of pre-RCA ionized calcium status. We arbitrarily used a 12-h window to define a pre-RCA iCa measurement, although this was consistent with our local practice. Because of the retrospective design and the way data were collected, we could not perform a formal sensitivity analysis using shorter windows, such as 6 h. As a result, some measurements obtained within this timeframe may not have fully reflected the immediate biochemical status at RCA initiation and may have led to some degree of misclassification. Also, the absence of a pre-treatment iCa measurement in some patients may reflect a higher degree of urgency at treatment initiation or the lack of systematic iCa assessment in all clinical settings or the absence of point-of-care testing in our center so that iCa was not immediately available at the bedside. In particular, in patients admitted for septic shock, unlike those with hemorrhagic shock, CRRT may have been started emergently before a pre-treatment iCa result was available. This may have contributed to selection bias and should be considered when interpreting the findings. Finally, the design of the study is associated with inherent bias related to its retrospective design; however, RCA-CRRT was strictly protocolized and blood sampling systematically performed during RCA-CRRT in all patients. Despite its limitations, the present study, conducted in a representative cohort of critically ill patients receiving standardized RCA-CRRT, including individuals with a low risk of bleeding as well as those with liver dysfunction provides clinically relevant descriptive data on calcium disturbances and RCA-related metabolic events. Future studies should extend these observations beyond the first 72 h of treatment and investigate whether pre-treatment calcium status is associated not only with early metabolic tolerance, but also with longer-term metabolic consequences and renal recovery. Conclusion The present study indicates ionized calcium blood measurement is not systematically performed prior to RCA-CRRT initiation. However, within the 12 h following RCA-CRRT initiation, most patients achieved normal calcium concentrations including those with pre-existing hypocalcemia. The occurrence of severe hypocalcemia below 1 mmol/L during the first 12 h appears to be associated with the existence of pre-existing severe hypocalcemia. Supplementary Information Supplementary Material 1. Acknowledgements The authors thank Véréna Landel (Direction de la Recherche en Santé, Hospices Civils de Lyon) for her help in manuscript preparation. Authors’ contributions BT, FB and TR participated in the study conception. BT; FB extracted the data.BT; FB; NC and TR drafted the manuscript. FB; MP performed the statistical analysis BT; FB; NC; RP; TR critically revised the manuscript for important intellectual content. All authors have critically reviewed the manuscript and agreed with the final version. Funding This research did not receive funding. Data availability The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate The study was approved by the Institutional Review Board of the Hospices Civils de Lyon (Comité Scientifique et Éthique des HCL, CSE-HCL; IRB 00013204; reference 24—5018) and was conducted in accordance with the Declaration of Helsinki. In accordance with French regulations for retrospective observational studies using routinely collected data, written informed consent to participate was not required. All participants and/or their next of kin were informed through an information letter and were given the opportunity to object to the use of their data; no objections were recorded. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.